US20160041145A1 - Detection And Quantification Of Acetylamantadine In Urine Samples - Google Patents

Detection And Quantification Of Acetylamantadine In Urine Samples Download PDF

Info

Publication number
US20160041145A1
US20160041145A1 US14/776,702 US201414776702A US2016041145A1 US 20160041145 A1 US20160041145 A1 US 20160041145A1 US 201414776702 A US201414776702 A US 201414776702A US 2016041145 A1 US2016041145 A1 US 2016041145A1
Authority
US
United States
Prior art keywords
acetylamantadine
urine sample
quantification
quantifying
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/776,702
Inventor
Reuven Gordon
Brian Cheng
Rashid Bux
Bram Ramjiawan
Aftab Ahmed
Fraser Alan Hof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomark Technologies Inc
Original Assignee
Biomark Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomark Technologies Inc filed Critical Biomark Technologies Inc
Priority to US14/776,702 priority Critical patent/US20160041145A1/en
Publication of US20160041145A1 publication Critical patent/US20160041145A1/en
Assigned to BIOMARK TECHNOLOGIES INC. reassignment BIOMARK TECHNOLOGIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOF, Fraser Alan, RAMJIAWAN, Bram, AHMED, Aftab, CHENG, BRIAN, GORDON, REUVEN, BUX, Rashid
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/02—Investigating particle size or size distribution
    • G01N15/0205—Investigating particle size or size distribution by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1434—Optical arrangements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Definitions

  • the present invention relates to the detection and quantification of biomarkers and, in particular, to the detection and quantification of acetylamantadine in urine samples.
  • Liquid chromatography mass spectrometry has been successfully employed to detect and quantify extremely low concentrations of acetylamantadine in biological samples such as urine. This may facilitate the diagnosis of cancer at an early stage as the quantification of acetylated forms of spermidine/spermine N 1 -acetyltransferase (SSAT) including amantadine may be used to detect various pathological conditions including cancer as disclosed in U.S. Pat. No. 6,811,967 which issued to Sitar et al. on Nov. 4, 2004, and the full disclosure of which is incorporated herein by reference.
  • SSAT acetylated forms of spermidine/spermine N 1 -acetyltransferase
  • the detection and quantification of acetylamantadine using liquid chromatography mass spectrometry is relatively time consuming and costly. There is accordingly a need for an efficient and cost effective method for detecting and quantifying acetylamantadine to allow for rapid economical testing
  • the method comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
  • the solid phase extraction may include eluting acetylamantadine with methanol.
  • the quantification of the acetylamantadine eluted from the urine sample using Raman spectroscopy may include the use of substrate based, surface-enhanced Raman spectroscopy.
  • the method disclosed herein may be used to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample.
  • the method disclosed herein may also be used to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
  • the method disclosed herein may be used to detect and quantify acetylamantadine at a low cost.
  • FIG. 1 shows the results of open air evaporation and slow evaporation of acetylamantadine in a methanol drop coated on a Surface Enhanced Raman Scattering (SERS) substrate;
  • SERS Surface Enhanced Raman Scattering
  • FIG. 2 shows quantification of acetylamantadine using a SERS substrate
  • FIG. 3 shows Raman spectra for different concentrations of acetylamantadine in a methanol
  • FIG. 4 shows a calibration curve based on the Raman spectra of FIG. 3 .
  • acetylamantadine a product of spermidine/spermine N 1 -acetyltransferase (SSAT) metabolism
  • Urine is a concentrated solution of many salts, polar metabolites and multiple non-polar steroids.
  • Expected concentration of acetylamantadine is about 1000 times smaller than that of amantadine in urine samples.
  • the distinction between amantadine and acetylamantadine can be based on the vibrational band of a carbonyl group at an approximately 1600 cm ⁇ 1 wavenumber. There are a few other differences between the spectra of amantadine and acetylamantadine, but this Raman band may be of particular interest as it is present only in the spectrum of acetylamantadine.
  • a urine sample was prepared and different constituents of the urine sample were separated using solid phase extraction (SPE).
  • SPE solid phase extraction
  • the urine sample is accordingly pre-treated using solid phase extraction to remove impurities prior to using Raman spectroscopy to identify and quantify acetylamantadine present in the urine sample.
  • the urine sample was treated using solid phase extraction to remove salts and polar impurities, increase the acetylamantadine to amantadine ratio, and minimize contamination from non-polar steroids.
  • the following protocol achieved all three aims using Strata X, Polymeric Reversed Phase from Phenomenex Inc of 411 Madrid Avenue, Torrance, Calif., 90501-1430.
  • Acetylamantadine in methanol is drop coated on the SERS substrate for Raman measurements.
  • the SERS substrate was a Klarite® SERS substrate from Renishaw Inc. of 5277 Trillium Boulevard, Hoffman Estates, Ill., 60192. Uniform coating of acetylamantadine over the SERS substrate assists in reliable quantification. It was observed that slow evaporation of methanol results in improved coating of acetylamantadine over the substrate.
  • FIG. 1 shows the results of open air evaporation and slow evaporation where the air flow is restricted. It can be seen that slow evaporation results in uniform coating.
  • FIG. 2 shows the quantification based on the 1600 cm ⁇ 1 band. The required resolution and limit of detection of 1 ng/mL is achieved with adequate signal to noise ratio. It will however be understood by a person skilled in the art that it is desirable to use a number of different peaks to create a calibration curve because different peaks will result in result in calibration curves having slightly different slopes.
  • FIG. 3 shows Raman measurements for acetylamantadine in methanol in the following concentrations 1 ng/mL, 5 g/mL, 10 ng/mL, 25 ng/mL and 50 ng/mL which were prepared using standard chemistry techniques to dissolve acetylamantadine in methanol.
  • Five peaks in the Raman spectra were chosen for each concentration, namely, 738 cm ⁇ 1 , 776.8 cm ⁇ 1 , 1198 cm ⁇ 1 , 1210 cm ⁇ 1 and 1436 cm ⁇ 1 .
  • Each peak was separated into a peak area and an adjacent area. Ten points were chosen in each peak area and adjacent area. The points were integrated and the number sum of peak area minus number sum of its adjacent area was used to get the intensity for each peak. It was then possible to get the Raman intensity for each concentration by integrating the five peaks as shown below.
  • I peak is the intensities in peak area and I adjacent is the intensities in adjacent area.
  • I peak is the intensities in peak area and I adjacent is the intensities in adjacent area.
  • the calibration curve may be used to detect and quantify the acetylamantadine in a urine sample.
  • Results demonstrate that acetylamantadine can be extracted from urine samples using solid phase extraction. Raman spectroscopy can then be used to simultaneously detect and quantify the acetylamantadine with a sensitivity of 1 ng/mL in the urine sample to screen a patient for a pathological condition such as cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the detection and quantification of biomarkers and, in particular, to the detection and quantification of acetylamantadine in urine samples.
  • 2. Description of the Related Art
  • Liquid chromatography mass spectrometry has been successfully employed to detect and quantify extremely low concentrations of acetylamantadine in biological samples such as urine. This may facilitate the diagnosis of cancer at an early stage as the quantification of acetylated forms of spermidine/spermine N1-acetyltransferase (SSAT) including amantadine may be used to detect various pathological conditions including cancer as disclosed in U.S. Pat. No. 6,811,967 which issued to Sitar et al. on Nov. 4, 2004, and the full disclosure of which is incorporated herein by reference. However, the detection and quantification of acetylamantadine using liquid chromatography mass spectrometry is relatively time consuming and costly. There is accordingly a need for an efficient and cost effective method for detecting and quantifying acetylamantadine to allow for rapid economical testing.
    • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide an improved method for detecting and quantifying acetylamantadine in urine samples.
  • There is accordingly provided a method for quantifying acetylamantadine in a urine sample. The method comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
  • The solid phase extraction may include eluting acetylamantadine with methanol. The quantification of the acetylamantadine eluted from the urine sample using Raman spectroscopy may include the use of substrate based, surface-enhanced Raman spectroscopy.
  • The method disclosed herein may be used to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample. The method disclosed herein may also be used to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
  • The method disclosed herein may be used to detect and quantify acetylamantadine at a low cost.
    • BRIEF DESCRIPTIONS OF DRAWINGS
  • The invention will be more readily understood from the following description of the embodiments thereof given, by way of example only, with reference to the accompanying drawings, in which:
  • FIG. 1 shows the results of open air evaporation and slow evaporation of acetylamantadine in a methanol drop coated on a Surface Enhanced Raman Scattering (SERS) substrate;
  • FIG. 2 shows quantification of acetylamantadine using a SERS substrate;
  • FIG. 3 shows Raman spectra for different concentrations of acetylamantadine in a methanol; and
  • FIG. 4 shows a calibration curve based on the Raman spectra of FIG. 3.
    •  DESCRIPTIONS OF THE PREFERRED EMBODIMENTS
  • Disclosed herein is the use of Raman spectroscopy to identify and quantify acetylamantadine, a product of spermidine/spermine N1-acetyltransferase (SSAT) metabolism, in urine samples. Urine is a concentrated solution of many salts, polar metabolites and multiple non-polar steroids. Expected concentration of acetylamantadine is about 1000 times smaller than that of amantadine in urine samples. The distinction between amantadine and acetylamantadine can be based on the vibrational band of a carbonyl group at an approximately 1600 cm−1 wavenumber. There are a few other differences between the spectra of amantadine and acetylamantadine, but this Raman band may be of particular interest as it is present only in the spectrum of acetylamantadine.
  • A urine sample was prepared and different constituents of the urine sample were separated using solid phase extraction (SPE). The urine sample is accordingly pre-treated using solid phase extraction to remove impurities prior to using Raman spectroscopy to identify and quantify acetylamantadine present in the urine sample.
    • Urine Sample
  • Artificial urine comprising the following components of urine NaCl 8.00 g/L, KCl 1.64 g/L, K2SO4 2.63 g/L, urea 13.40 g/L, and creatinine 1.50 g/L was used to prepare a urine sample having corticosterone 16.7 mM, amantadine 3.3 mM, and acetylamantadine 3.3 uM.
    • Solid Phase Extraction (SPE)
  • The urine sample was treated using solid phase extraction to remove salts and polar impurities, increase the acetylamantadine to amantadine ratio, and minimize contamination from non-polar steroids. The following protocol achieved all three aims using Strata X, Polymeric Reversed Phase from Phenomenex Inc of 411 Madrid Avenue, Torrance, Calif., 90501-1430.
  • (1) Prime: 2 mL MeOH, 2 mL deionized H2O, 2 mL 50 mM pH 7.0 phosphate buffer.
  • (2) Load: Combine 2 mL of urine sample with 2 mL of 50 mM pH 7.0 phosphate buffer and load onto SPE cartridge.
  • (3) Wash 1: 2 mL deionized H2O, 2×1.5 mL 50 mM pH 7.0 phosphate buffer (salts and polar metabolites elute with this fraction).
  • (4) Wash 2: 2×2 mL 40% methanol in H2O2O (amantadine elutes with this fraction while acetylamantadine and the less polar steroid corticosterone is retained).
  • (5) Wash 3: 2 mL 100% methanol (acetylamantadine elutes with this fraction while corticosterone is retained).
  • (6) Dry column by flushing air through it for a few minutes.
  • (7) Eluent: 2 mL ethyl acetate (corticosterone elutes).
    • Coating of acetylamantadine over Surface Enhanced Raman Scattering (SERS) Substrate
  • Acetylamantadine in methanol, obtained from Wash 3 of SPE protocol above, is drop coated on the SERS substrate for Raman measurements. In this example, the SERS substrate was a Klarite® SERS substrate from Renishaw Inc. of 5277 Trillium Boulevard, Hoffman Estates, Ill., 60192. Uniform coating of acetylamantadine over the SERS substrate assists in reliable quantification. It was observed that slow evaporation of methanol results in improved coating of acetylamantadine over the substrate. FIG. 1 shows the results of open air evaporation and slow evaporation where the air flow is restricted. It can be seen that slow evaporation results in uniform coating.
    • Raman Measurements
  • In this example, 30 uL of acetylamantadine in methanol was drop coated on the SERS substrate and allowed to dry slowly. A Raman map of 170 mesh points was collected with 1 second of integration at each mesh point. Out of the 170 spectra, only those were retained which showed Raman peaks, the rest were neglected. FIG. 2 shows the quantification based on the 1600 cm−1 band. The required resolution and limit of detection of 1 ng/mL is achieved with adequate signal to noise ratio. It will however be understood by a person skilled in the art that it is desirable to use a number of different peaks to create a calibration curve because different peaks will result in result in calibration curves having slightly different slopes.
    • Raman Data and Analysis Used to Create a Calibration Curve
  • FIG. 3 shows Raman measurements for acetylamantadine in methanol in the following concentrations 1 ng/mL, 5 g/mL, 10 ng/mL, 25 ng/mL and 50 ng/mL which were prepared using standard chemistry techniques to dissolve acetylamantadine in methanol. Five peaks in the Raman spectra were chosen for each concentration, namely, 738 cm−1, 776.8 cm−1, 1198 cm−1, 1210 cm−1 and 1436 cm−1.
  • Each peak was separated into a peak area and an adjacent area. Ten points were chosen in each peak area and adjacent area. The points were integrated and the number sum of peak area minus number sum of its adjacent area was used to get the intensity for each peak. It was then possible to get the Raman intensity for each concentration by integrating the five peaks as shown below.
  • ∑ n = 5 ( ∑ n_peak = 10 I peak - ∑ n_adjacent = 10 I adjacent )
  • Where Ipeak is the intensities in peak area and Iadjacent is the intensities in adjacent area. The sum of intensities for each concentration were then plotted to create the calibration curves shown in FIG. 4 which also shows the revalidation of the analysis. The calibration curve may be used to detect and quantify the acetylamantadine in a urine sample.
    • Conclusion
  • Results demonstrate that acetylamantadine can be extracted from urine samples using solid phase extraction. Raman spectroscopy can then be used to simultaneously detect and quantify the acetylamantadine with a sensitivity of 1 ng/mL in the urine sample to screen a patient for a pathological condition such as cancer.
  • It will be understood by a person skilled in the art that many of the details provided above are by way of example only, and are not intended to limit the scope of the invention which is to be determined with reference to the following claims.

Claims (6)

1. A method for quantifying acetylamantadine in a urine sample, the method comprising:
eluting acetylamantadine from the urine sample using solid phase extraction; and
quantifying the acetylamantadine eluted from the urine sample using substrate based, surface enhanced Raman spectroscopy.
2. The method as claimed in claim 1 wherein the solid phase extraction includes eluting acetylamantadine with methanol.
3. The method as claimed in claim 1 wherein quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy includes quantifying the acetylamantadine based on a 1600 cm−1 band.
4. The method as claimed in claim 1 wherein quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy includes quantifying the acetylamantadine with a sensitivity of 1 mg/mL.
5. Use of the method as claimed in claim 1 to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample.
6. Use of the method as claimed in claim 1 to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
US14/776,702 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples Abandoned US20160041145A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/776,702 US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785159P 2013-03-14 2013-03-14
PCT/CA2014/050273 WO2014139025A1 (en) 2013-03-14 2014-03-14 Detection and quantification of acetylamantadine in urine samples
US14/776,702 US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2014/050273 A-371-Of-International WO2014139025A1 (en) 2013-03-14 2014-03-14 Detection and quantification of acetylamantadine in urine samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/645,994 Continuation US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Publications (1)

Publication Number Publication Date
US20160041145A1 true US20160041145A1 (en) 2016-02-11

Family

ID=51535742

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/776,702 Abandoned US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples
US15/645,994 Active US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/645,994 Active US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Country Status (5)

Country Link
US (2) US20160041145A1 (en)
EP (1) EP2999964A4 (en)
CN (1) CN105209910B (en)
CA (2) CA3212686A1 (en)
WO (1) WO2014139025A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205960A1 (en) * 2015-06-26 2016-12-29 Biomark Cancer Systems Inc. Method of detecting lung cancer
CN106290338B (en) * 2016-09-10 2019-02-22 上海大学 A method of detection amantadine content
CN110426386A (en) * 2019-09-11 2019-11-08 深圳网联光仪科技有限公司 A kind of Surface enhanced Raman spectroscopy detection pharmaceutical methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811967B2 (en) * 2001-03-02 2004-11-02 The University Of Manitoba Method for assaying non-spermine/spermidine activity of spermidine/spermine N1-acetyltransferase (SSAT)
US8102525B2 (en) * 2008-10-07 2012-01-24 OptoTrace (SuZhou) Technologies, Inc. Systems and methods for detecting chemical and biological substances
CN101198847A (en) * 2005-04-14 2008-06-11 化学影像公司 Method and applications to enhance and image optical signals from biological objects
US7656523B2 (en) * 2006-06-30 2010-02-02 Intel Corporation Multiplexed raman detection with filter set
WO2009105520A2 (en) * 2008-02-19 2009-08-27 University Of Georgia Research Foundation Methods, devices, and compositions for the highly-sensitive detection and identification of diverse molecular entities
CN102947681B (en) * 2010-04-20 2016-05-18 惠普发展公司，有限责任合伙企业 Strengthen luminous automatic layout, luminous enhance device for surface
JP5519075B2 (en) * 2010-04-20 2014-06-11 ヒューレット−パッカード デベロップメント カンパニー エル．ピー． Multi-columnar structural elements for molecular analysis
US9410949B2 (en) * 2010-12-03 2016-08-09 Washington University In St. Louis Label-free detection of renal cancer
WO2012151702A1 (en) * 2011-05-10 2012-11-15 Biomark Technologies Inc. Monoclonal antibody for acetylamantadine

Also Published As

Publication number Publication date
CN105209910A (en) 2015-12-30
CN105209910B (en) 2019-02-15
EP2999964A4 (en) 2017-03-01
CA2906236C (en) 2023-10-31
CA3212686A1 (en) 2014-09-18
EP2999964A1 (en) 2016-03-30
WO2014139025A1 (en) 2014-09-18
US10175226B2 (en) 2019-01-08
CA2906236A1 (en) 2014-09-18
US20170328881A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
Jakimska et al. Development of a liquid chromatography–tandem mass spectrometry procedure for determination of endocrine disrupting compounds in fish from Mediterranean rivers
US10175226B2 (en) Detection and quantification of acetylamantadine in urine samples
Beck et al. Analysis for Cd, Cu, Ni, Zn, and Mn in estuarine water by inductively coupled plasma mass spectrometry coupled with an automated flow injection system
González et al. Development and validation of an ultra-high performance liquid chromatography–tandem mass-spectrometry (UHPLC–MS/MS) method for the simultaneous determination of neurotransmitters in rat brain samples
Li et al. Rapid simultaneous determination of dexamethasone and betamethasone in milk by liquid chromatography tandem mass spectrometry with isotope dilution
Velghe et al. Fully automated therapeutic drug monitoring of anti-epileptic drugs making use of dried blood spots
Wang et al. Solid phase microextraction combined with thermal-desorption electrospray ionization mass spectrometry for high-throughput pharmacokinetics assays
KR101228322B1 (en) Quantitative analytic method for steroid hormones in saliva
Li et al. Reversed-phase liquid chromatography/electrospray ionization/mass spectrometry with isotope dilution for the analysis of nitrate and nitrite in water
Alvarez et al. Determination of calcium, potassium, manganese, iron, copper and zinc levels in representative samples of two onion cultivars using total reflection X-ray fluorescence and ultrasound extraction procedure
Sitko et al. Liquid-phase microextraction as an attractive tool for multielement trace analysis in combination with X-ray fluorescence spectrometry: An example of simultaneous determination of Fe, Co, Zn, Ga, Se and Pb in water samples
Allende et al. LC–MS/MS method for the simultaneous determination of free urinary steroids
Chang et al. A high-throughput method based on microwave-assisted extraction and liquid chromatography–tandem mass spectrometry for simultaneous analysis of amphetamines, ketamine, opiates, and their metabolites in hair
Sloop et al. Automated matrix-matching calibration using standard dilution analysis with two internal standards and a simple three-port mixing chamber
Rivera et al. Influence of natural organic matter on the screening of pharmaceuticals in water by using liquid chromatography with full scan mass spectrometry
Xu et al. A strategy for the evaluation of an analytical approach for selected pesticide residues in complex agricultural product matrices—A case study of leek
Camino-Sánchez et al. Validation of a method for the determination of tributyltin in seawater by stir bar sorptive extraction–liquid chromatography tandem mass spectrometry
Pan et al. Comparison of different calibration approaches for chloramphenicol quantification in chicken muscle by ultra-high pressure liquid chromatography tandem mass spectrometry
Lu et al. Detection of cocaine and its metabolites in urine using solid phase extraction-ion mobility spectrometry with alternating least squares
Alfarhani et al. Room temperature fluorescence spectroscopy of benzo [a] pyrene metabolites on octadecyl extraction membranes
Minakata et al. Determination of iodide in urine using electrospray ionization tandem mass spectrometry
Boyer et al. Detection of testosterone propionate administration in horse hair samples
CN108982466A (en) A method of for antibiotic field quick detection in Amoxicillin in water body
CN113267589B (en) Analysis method of 16 synthetic cannabinoids and metabolites thereof in hair
KR20090027896A (en) Method for analysis of polyamines in urine or plasma using liquid chromatography/electronspray ionization-tandem mass spectrometry along with amine carbamylated derivatization

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIOMARK TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORDON, REUVEN;CHENG, BRIAN;BUX, RASHID;AND OTHERS;SIGNING DATES FROM 20130326 TO 20130410;REEL/FRAME:043817/0751